US6025372A
(en)
*
|
1997-04-04 |
2000-02-15 |
Merck & Co., Inc. |
Somatostatin agonists
|
GB9819860D0
(en)
|
1998-09-12 |
1998-11-04 |
Zeneca Ltd |
Chemical compounds
|
EP1117662A1
(en)
*
|
1998-09-30 |
2001-07-25 |
Merck Sharp & Dohme Limited |
Benzimidazolinyl piperidines as cgrp ligands
|
DE19911039A1
(de)
*
|
1999-03-12 |
2000-09-14 |
Boehringer Ingelheim Pharma |
Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
US6387932B1
(en)
|
1999-06-25 |
2002-05-14 |
Merck & Co., Inc. |
Somatostatin agonists
|
DE19937304C2
(de)
*
|
1999-08-10 |
2003-08-21 |
Boehringer Ingelheim Pharma |
Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
DE19952146A1
(de)
*
|
1999-10-29 |
2001-06-07 |
Boehringer Ingelheim Pharma |
Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
DE19952147A1
(de)
*
|
1999-10-29 |
2001-05-03 |
Boehringer Ingelheim Pharma |
Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
EP1226132A1
(en)
|
1999-11-04 |
2002-07-31 |
Ortho-McNeil Pharmaceutical, Inc. |
Nonpeptide substituted benzothiazepines as vasopressin antagonists
|
DE19963868A1
(de)
*
|
1999-12-30 |
2001-07-12 |
Boehringer Ingelheim Pharma |
Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
NZ520240A
(en)
|
2000-03-06 |
2005-04-29 |
Acadia Pharm Inc |
Azacyclic compounds for use in the treatment of serotonin related diseases
|
AR033517A1
(es)
|
2000-04-08 |
2003-12-26 |
Astrazeneca Ab |
Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
|
US6653478B2
(en)
|
2000-10-27 |
2003-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
|
MXPA03007857A
(es)
*
|
2001-03-01 |
2004-05-24 |
Emisphere Tech Inc |
Compuestos y composiciones para entregar agentes activos.
|
GB0108876D0
(en)
*
|
2001-04-09 |
2001-05-30 |
Novartis Ag |
Organic Compounds
|
DE60231257D1
(de)
*
|
2001-04-18 |
2009-04-02 |
Euro Celtique Sa |
1-(4-piperidinyl)-1,3-dihydro-2h-indol-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz
|
RU2004100839A
(ru)
|
2001-07-02 |
2005-06-20 |
Астразенека Аб (Se) |
Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
|
US6977264B2
(en)
*
|
2001-07-25 |
2005-12-20 |
Amgen Inc. |
Substituted piperidines and methods of use
|
US7115607B2
(en)
*
|
2001-07-25 |
2006-10-03 |
Amgen Inc. |
Substituted piperazinyl amides and methods of use
|
US20030181462A1
(en)
*
|
2001-08-17 |
2003-09-25 |
Boehringer Ingelheim Pharma Kg |
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
|
DE10139410A1
(de)
*
|
2001-08-17 |
2003-02-27 |
Boehringer Ingelheim Pharma |
Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
|
GB0120461D0
(en)
|
2001-08-22 |
2001-10-17 |
Astrazeneca Ab |
Novel compounds
|
GB0122503D0
(en)
|
2001-09-18 |
2001-11-07 |
Astrazeneca Ab |
Chemical compounds
|
DE60236206D1
(de)
|
2001-12-28 |
2010-06-10 |
Acadia Pharm Inc |
Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
|
DE10206770A1
(de)
*
|
2002-02-19 |
2003-08-28 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
|
US6900317B2
(en)
*
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
US7026312B2
(en)
*
|
2002-03-14 |
2006-04-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
SE0200843D0
(sv)
|
2002-03-19 |
2002-03-19 |
Astrazeneca Ab |
Chemical compounds
|
SE0200844D0
(sv)
|
2002-03-19 |
2002-03-19 |
Astrazeneca Ab |
Chemical compounds
|
CN100558728C
(zh)
*
|
2002-06-05 |
2009-11-11 |
布里斯托尔-迈尔斯斯奎布公司 |
降钙素基因相关肽受体拮抗剂
|
US7220862B2
(en)
|
2002-06-05 |
2007-05-22 |
Bristol-Myers Squibb Company |
Calcitonin gene related peptide receptor antagonists
|
US7842808B2
(en)
*
|
2002-06-05 |
2010-11-30 |
Bristol-Myers Squibb Company |
Anti-migraine spirocycles
|
DE10227294A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
|
US20040076587A1
(en)
*
|
2002-06-19 |
2004-04-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical composition for intranasal administration containing a CGRP antagonist
|
WO2004000808A2
(en)
|
2002-06-24 |
2003-12-31 |
Acadia Pharmaceuticals Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
US7253186B2
(en)
|
2002-06-24 |
2007-08-07 |
Carl-Magnus Andersson |
N-substituted piperidine derivatives as serotonin receptor agents
|
US7538222B2
(en)
|
2002-06-24 |
2009-05-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
GB0218326D0
(en)
*
|
2002-08-07 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
EP1539735A4
(en)
*
|
2002-09-11 |
2006-07-26 |
Merck & Co Inc |
PIPERAZINE UREA DERIVATIVES AS AGONISTS ON MELANOCORTIN-4 RECEPTOR
|
DE10250082A1
(de)
*
|
2002-10-25 |
2004-05-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7595312B2
(en)
*
|
2002-10-25 |
2009-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
|
DE10300973A1
(de)
*
|
2003-01-14 |
2004-07-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
NZ541146A
(en)
|
2003-01-16 |
2009-04-30 |
Acadia Pharm Inc |
N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide, also known as ACP-103, and its tartrate salt as therapeutics for neurodegenerative diseases
|
SE0300957D0
(sv)
|
2003-04-01 |
2003-04-01 |
Astrazeneca Ab |
Chemical compounds
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
US20050042180A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
US20050065094A1
(en)
|
2003-09-05 |
2005-03-24 |
Boehringer Ingelheim International Gmbh |
Use of telmisartan for the prevention and treatment of vascular headache
|
KR100661118B1
(ko)
*
|
2003-11-12 |
2006-12-26 |
주식회사 엘지생명과학 |
멜라노코틴 수용체의 항진제
|
EA009875B1
(ru)
|
2003-11-20 |
2008-04-28 |
Янссен Фармацевтика Н.В. |
6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
|
CA2546002C
(en)
*
|
2003-11-20 |
2012-09-18 |
Janssen Pharmaceutica N.V. |
7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
BRPI0416532A
(pt)
*
|
2003-12-05 |
2007-01-09 |
Janssen Pharmaceutica Nv |
2-quinolinonas e 2-quinoxalinonas substituìdas por 6 como inibidores da poli(adp-ribose) polimerase
|
AR046787A1
(es)
*
|
2003-12-05 |
2005-12-21 |
Bristol Myers Squibb Co |
Agentes antimigrana heterociclicos
|
AU2003297694A1
(en)
|
2003-12-05 |
2005-08-12 |
Bristol-Myers Squibb Company |
Calcitonin gene related peptide receptor antagonists
|
DE102004006893A1
(de)
*
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
|
US20050192230A1
(en)
*
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim International Gambh |
Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
TW200533398A
(en)
|
2004-03-29 |
2005-10-16 |
Bristol Myers Squibb Co |
Novel therapeutic agents for the treatment of migraine
|
DE102004015723A1
(de)
*
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7547694B2
(en)
*
|
2004-04-15 |
2009-06-16 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
DE102004018796A1
(de)
*
|
2004-04-15 |
2005-11-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004018794A1
(de)
*
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US20050282857A1
(en)
*
|
2004-04-15 |
2005-12-22 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
DE102004018795A1
(de)
*
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US20050233980A1
(en)
*
|
2004-04-20 |
2005-10-20 |
Boehringer Ingelheim International Gmbh |
CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
|
US7696195B2
(en)
*
|
2004-04-22 |
2010-04-13 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
DE102004019492A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US20050261278A1
(en)
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US7820695B2
(en)
|
2004-05-21 |
2010-10-26 |
Acadia Pharmaceuticals, Inc. |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
EA011552B1
(ru)
*
|
2004-06-30 |
2009-04-28 |
Янссен Фармацевтика Н.В. |
Производные хиназолиндиона в качестве ингибиторов parp
|
ATE540936T1
(de)
|
2004-06-30 |
2012-01-15 |
Janssen Pharmaceutica Nv |
Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
|
US7803795B2
(en)
*
|
2004-06-30 |
2010-09-28 |
Janssen Pharmaceutica N.V. |
Phthalazine derivatives as parp inhibitors
|
ES2412207T3
(es)
|
2004-09-27 |
2013-07-10 |
Acadia Pharmaceuticals Inc. |
Forma cristalina de hemitartrato de N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida
|
US7790899B2
(en)
|
2004-09-27 |
2010-09-07 |
Acadia Pharmaceuticals, Inc. |
Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
|
US7384931B2
(en)
*
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
US7384930B2
(en)
|
2004-11-03 |
2008-06-10 |
Bristol-Myers Squibb Company |
Constrained compounds as CGRP-receptor antagonists
|
US7449586B2
(en)
*
|
2004-12-03 |
2008-11-11 |
Bristol-Myers Squibb Company |
Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
|
DE102004063753A1
(de)
*
|
2004-12-29 |
2006-07-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
|
DE102004063755A1
(de)
*
|
2004-12-29 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
|
DE102004063752A1
(de)
*
|
2004-12-29 |
2006-07-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
|
EP1770091A1
(de)
*
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7491717B2
(en)
*
|
2005-03-23 |
2009-02-17 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
US7439237B2
(en)
*
|
2005-04-15 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
KR20080037655A
(ko)
|
2005-07-21 |
2008-04-30 |
아스트라제네카 아베 |
신규 피페리딘 유도체
|
DE102005038831A1
(de)
*
|
2005-08-17 |
2007-02-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US7834007B2
(en)
*
|
2005-08-25 |
2010-11-16 |
Bristol-Myers Squibb Company |
CGRP antagonists
|
DE102005042828A1
(de)
*
|
2005-09-09 |
2007-03-22 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGPR-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP1770087A1
(de)
*
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
EP1770086A1
(de)
*
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102005050892A1
(de)
*
|
2005-10-21 |
2007-04-26 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
RS20080200A
(en)
|
2005-11-14 |
2009-07-15 |
Rinat Neuroscience Corp., |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
AU2006316627A1
(en)
*
|
2005-11-18 |
2007-05-31 |
Merck Sharp & Dohme Corp. |
Spirolactam aryl CGRP receptor antagonists
|
US7601844B2
(en)
*
|
2006-01-27 |
2009-10-13 |
Bristol-Myers Squibb Company |
Piperidinyl derivatives as modulators of chemokine receptor activity
|
WO2007115805A2
(en)
*
|
2006-04-05 |
2007-10-18 |
European Molecular Biology Laboratory (Embl) |
Aurora kinase inhibitors
|
DE102006017827A1
(de)
*
|
2006-04-13 |
2007-10-18 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue kristalline Verbindungen
|
TW200813018A
(en)
|
2006-06-09 |
2008-03-16 |
Astrazeneca Ab |
Novel compounds
|
WO2008079945A2
(en)
*
|
2006-12-20 |
2008-07-03 |
University Of South Florida |
Rock inhibitors and uses thereof
|
AU2008223793B2
(en)
|
2007-03-08 |
2012-08-23 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as PARP and TANK inhibitors
|
US20090053329A1
(en)
|
2007-03-19 |
2009-02-26 |
Acadia Pharmaceuticals, Inc. |
Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
|
US8119661B2
(en)
|
2007-09-11 |
2012-02-21 |
Astrazeneca Ab |
Piperidine derivatives and their use as muscarinic receptor modulators
|
JP5525447B2
(ja)
|
2007-10-26 |
2014-06-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Parp阻害剤としてのキノリノン誘導体
|
EP3441087A1
(en)
|
2008-03-04 |
2019-02-13 |
Teva Pharmaceuticals International GmbH |
Methods of treating chronic pain
|
PL2265288T3
(pl)
|
2008-03-04 |
2017-01-31 |
Labrys Biologics Inc |
Sposoby leczenia bólu zapalnego
|
WO2009118384A1
(en)
|
2008-03-27 |
2009-10-01 |
Janssen Pharmaceutica Nv |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
MX2010010406A
(es)
|
2008-03-27 |
2010-10-25 |
Janssen Pharmaceutica Nv |
Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
|
TWI433838B
(zh)
|
2008-06-25 |
2014-04-11 |
必治妥美雅史谷比公司 |
作為趨化因子受體活性調節劑之六氫吡啶衍生物
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
US8623366B2
(en)
|
2009-08-28 |
2014-01-07 |
Labrys Biologics, Inc. |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
US8642622B2
(en)
|
2010-06-16 |
2014-02-04 |
Bristol-Myers Squibb Company |
Piperidinyl compound as a modulator of chemokine receptor activity
|
EP3508501A1
(en)
|
2011-05-20 |
2019-07-10 |
AlderBio Holdings LLC |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
PL2710039T3
(pl)
|
2011-05-20 |
2019-07-31 |
Alderbio Holdings Llc |
Kompozycje przeciwko CGRP i ich zastosowanie
|
TWI609888B
(zh)
|
2011-05-20 |
2018-01-01 |
艾爾德生物控股有限責任公司 |
抗降血鈣素基因相關胜肽(anti-cgrp)或抗降血鈣素基因相關胜肽受器(anti-cgrp-r)抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
|
JP5988087B2
(ja)
*
|
2012-06-07 |
2016-09-07 |
Dic株式会社 |
化合物の製造方法
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
HRP20240159T1
(hr)
|
2014-03-21 |
2024-04-12 |
Teva Pharmaceuticals International Gmbh |
Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
|
SI3325444T1
(sl)
|
2015-07-20 |
2021-11-30 |
Acadia Pharmaceuticals Inc. |
Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
|
GB201519196D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP Receptor Antagonists
|
GB201519195D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP Receptor Antagonists
|
GB201519194D0
(en)
|
2015-10-30 |
2015-12-16 |
Heptares Therapeutics Ltd |
CGRP receptor antagonists
|
US10953000B2
(en)
|
2016-03-25 |
2021-03-23 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome P450 modulators
|
WO2017165635A1
(en)
|
2016-03-25 |
2017-09-28 |
Acadia Pharmaceuticals Inc. |
Combination of pimavanserin and cytochrome p450 modulators
|
PE20191148A1
(es)
|
2016-09-23 |
2019-09-02 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento de la migrana refractaria
|
EP3558311A1
(en)
|
2016-12-20 |
2019-10-30 |
Acadia Pharmaceuticals Inc. |
Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
|
WO2018200977A1
(en)
|
2017-04-28 |
2018-11-01 |
Acadia Pharmaceuticals Inc. |
Pimavanserin for treating impulse control disorder
|
US20210077479A1
(en)
|
2017-08-30 |
2021-03-18 |
Acadia Pharmaceuticals Inc. |
Formulations of pimavanserin
|
JP2022516956A
(ja)
|
2019-01-08 |
2022-03-03 |
ハー・ルンドベック・アクチエゼルスカベット |
抗cgrp抗体を用いた頭痛の急性治療及び迅速治療
|
MX2023010115A
(es)
|
2021-03-02 |
2023-11-09 |
Cgrp Diagnostics Gmbh |
Tratamiento y/o reducción de la aparición de la migraña.
|
WO2023026205A1
(en)
|
2021-08-24 |
2023-03-02 |
Cgrp Diagnostics Gmbh |
Preventative treatment of migraine
|
WO2024100171A1
(en)
|
2022-11-11 |
2024-05-16 |
Boehringer Ingelheim International Gmbh |
Olcegepant for treating sepsis
|